JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balasubramaniam, G.
Right arrow Articles by Mah, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balasubramaniam, G.
Right arrow Articles by Mah, S. C.

Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats

G Balasubramaniam, HS Lee and SC Mah

Department of Pharmacology, Faculty of Medicine, National University of Singapore, Kent Ridge.

The antihypertensive mode of action of the 5HT2 receptor antagonist, ketanserin (KET), is still a subject of controversy and has been evaluated predominantly in acute studies. Acute i.v. administration of KET (3.0 or 6.0 mg/kg) in spontaneously hypertensive rats resulted in dose-dependent reductions in mean arterial pressure accompanied by concomitant bradycardia. In these studies, the responses to single i.v. doses of the alpha-1 adrenoceptor agonist phenylephrine (10.0 micrograms/kg) and to the 5HT2 receptor agonist alpha-methyl-5- hydroxytryptamine (125.0 micrograms/kg) 30 min after injection of KET were blocked. In spontaneously hypertensive rats treated with KET infusions (3.0 mg/kg/day i.v., n = 9, or 6.0 mg/kg/day i.v., n = 8) for 7 days via osmotic minipumps, significant dose-dependent falls in systolic blood pressure were observed during the period of infusion. Heart rate did not change over the period of observation in both vehicle- and KET-treated groups. On day 7 of infusion, KET dose- dependently reduced responses to the 5HT2 agonist alpha-methyl-5- hydroxytryptamine (5.0-125.0 micrograms/kg i.v.) but did not affect responses to phenylephrine (1.0-10.0 micrograms/kg i.v.). Baroreflex sensitivity on day 7 was significantly greater in KET-infused rats as compared with control rats. These data confirm that the acute antihypertensive effects of KET are due to a combination of alpha-1 and 5HT2 receptor blockade. During chronic administration, however, the alpha-1 blocking effects of KET are compensated for, and the reduction in blood pressure by day 7 of KET chronic administration is maintained predominantly by persistent blockade of 5HT2 receptors.

Volume 264, Issue 1, pp. 129-134, 01/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics.